^
Association details:
| Biomarker: | PTEN overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) + xentuzumab (BI-836845) (IGF-2 inhibitor, IGF1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Published date:
08/04/2023
Excerpt:
Subgroup analysis suggested trends towards benefit with Xe1000 + En160 in patients whose tumours had high levels of IGF1 mRNA or PTEN protein.
DOI:
10.1038/s41416-023-02380-1
Trial ID:
